Lung Squamous Cell Carcinoma with EML4-ALK Fusion and TP53 Co-mutation
Treated with Ensartinib: A Case Report and Literature Review / 中国肺癌杂志
Chinese Journal of Lung Cancer
; (12): 78-82, 2023.
Article
in Zh
| WPRIM
| ID: wpr-971182
Responsible library:
WPRO
ABSTRACT
Lung squamous cell carcinoma (LSCC) accounts for approximately 30% of non-small cell lung cancer (NSCLC) cases and is the second most common histological type of lung cancer. Anaplastic lymphoma kinase (ALK)-positive NSCLC accounts for only 2%-5% of all NSCLC cases, and is almost exclusively detected in patients with lung adenocarcinoma. Thus, ALK testing is not routinely performed in the LSCC population, and the efficacy of such treatment for ALK-rearranged LSCC remains unknown. Echinoderm microtubule associated protein like 4 (EML4)-ALK (V1) and TP53 co-mutations were identified by next generation sequencing (NGS) in this patient with advanced LSCC. On December 3, 2020, Ensatinib was taken orally and the efficacy was evaluated as partial response (PR). The progression-free survival (PFS) was 19 months. When the disease progressed, the medication was changed to Loratinib. To our knowledge, Enshatinib created the longest PFS of ALK-mutant LSCC patients treated with targeted therapy since literature review. Herein, we described one case treated by Enshatinib involving a patient with both EML4-ALK and TP53 positive LSCC, and the relevant literatures were reviewed for discussing the treatment of this rare disease.
.
Key words
Full text:
1
Database:
WPRIM
Main subject:
Carcinoma, Squamous Cell
/
Oncogene Proteins, Fusion
/
Tumor Suppressor Protein p53
/
Carcinoma, Non-Small-Cell Lung
/
Cytoskeletal Proteins
/
Protein Kinase Inhibitors
/
Anaplastic Lymphoma Kinase
/
Lung
/
Lung Neoplasms
/
Mutation
Limits:
Humans
Language:
Zh
Journal:
Chinese Journal of Lung Cancer
Year:
2023
Type:
Article